FATE
Company Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.65M | 13.63M | 63.53M | 96.30M | 55.85M | 31.43M | 10.68M | 4.74M | 4.11M | 4.40M | 2.43M | 0 |
| Net Income | (136.31M) | (186.26M) | (160.93M) | (281.72M) | (212.15M) | (173.39M) | (98.15M) | (66.60M) | (42.95M) | (33.46M) | (29.99M) | (25.88M) |
| EPS | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 |
| Free Cash Flow | (112.04M) | (123.60M) | (138.42M) | (283.77M) | (213.57M) | (44.16M) | (90.57M) | (40.95M) | (38.63M) | (30.28M) | N/A | N/A |
| FCF / Share | -0.94 | -1.09 | -1.41 | -2.93 | -2.25 | -0.54 | -1.33 | -0.73 | -0.92 | -0.95 | N/A | N/A |
| Operating CF | (106.08M) | (122.87M) | (132.26M) | (248.21M) | (162.87M) | (39.23M) | (83.17M) | (38.65M) | (36.91M) | (29.82M) | N/A | N/A |
| Total Assets | 318.94M | 440.69M | 506.22M | 705.56M | 921.46M | 622.46M | 302.27M | 213.03M | 105.29M | 95.05M | N/A | N/A |
| Total Debt | 77.85M | 85.27M | 103.54M | 109.34M | 114.82M | 97.30M | 26.93M | 14.88M | 14.81M | 10.69M | N/A | N/A |
| Cash & Equiv | 46.63M | 36.06M | 41.87M | 61.33M | 133.58M | 167.35M | 99.81M | 190.51M | 88.95M | 88.61M | N/A | N/A |
| Book Value | 207.18M | 318.73M | 368.42M | 483.94M | 678.84M | 384.44M | 244.76M | 160.47M | 77.19M | 73.15M | N/A | N/A |
| Return on Equity | -0.66 | -0.58 | -0.44 | -0.58 | -0.31 | -0.45 | -0.40 | -0.42 | -0.56 | -0.46 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30M | 1.37M | 1.74M | 1.91M | 1.63M | 1.86M | 3.07M | 6.77M | 1.93M | 1.68M | 1.94M | 933,000 |
| Net Income | (31.21M) | (32.37M) | (32.25M) | (34.07M) | (37.62M) | (52.15M) | (47.68M) | (38.43M) | (48.00M) | (44.12M) | (45.17M) | (52.76M) |
| EPS | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
| Free Cash Flow | (31.06M) | (24.51M) | (26.58M) | (25.95M) | (35.01M) | (27.90M) | (29.91M) | (32.36M) | (33.44M) | (36.82M) | (38.84M) | (30.69M) |
| FCF / Share | -0.26 | -0.21 | -0.22 | -0.22 | -0.30 | -0.24 | -0.25 | -0.28 | -0.33 | -0.37 | -0.39 | -0.31 |
| Operating CF | (30.82M) | (23.31M) | (24.37M) | (24.59M) | (33.81M) | (27.80M) | (29.42M) | (32.31M) | (33.35M) | (36.64M) | (38.27M) | (28.49M) |
| Total Assets | 284.92M | 318.94M | 343.67M | 371.63M | 398.67M | 440.69M | 494.97M | 528.82M | 569.89M | 506.22M | 543.79M | 584.76M |
| Total Debt | 76.78M | 77.85M | 79.25M | 81.33M | 83.33M | 85.27M | 98.98M | 100.56M | 102.07M | 103.54M | 104.95M | 106.35M |
| Cash & Equiv | 39.57M | 46.63M | 40.62M | 41.25M | 44.92M | 36.06M | 37.91M | 36.92M | 121.32M | 41.87M | 33.33M | 46.80M |
| Book Value | 179.71M | 207.18M | 234.07M | 261.36M | 288.41M | 318.73M | 362.33M | 396.98M | 426.12M | 368.42M | 402.78M | 437.75M |
| Return on Equity | -0.17 | -0.16 | -0.14 | -0.13 | -0.13 | -0.16 | -0.13 | -0.10 | -0.11 | -0.12 | -0.11 | -0.12 |
